Which Weight Loss Injectable Delivers Better UK Results?
Understanding Mounjaro and Wegovy Weight Loss Results in UK Patients
The weight loss results from Mounjaro and Wegovy stem from fundamentally different mechanisms, making direct comparisons challenging. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro utilises tirzepatide, a dual-action treatment targeting both GIP and GLP-1 receptors, potentially affecting metabolism through multiple pathways.
UK patients often ask which treatment delivers superior results, but the answer depends on individual factors including medical history, lifestyle, and response to medication. Both prescription-only medicines require clinical assessment and ongoing monitoring through registered healthcare providers. EverydayMeds' UK prescribers evaluate each patient's suitability for Mounjaro and Wegovy based on MHRA-approved criteria, ensuring safe and appropriate treatment selection.
Mounjaro and Wegovy Pricing: Complete UK Cost Breakdown
Understanding the full cost implications of Mounjaro and Wegovy helps UK patients budget effectively for their weight management journey. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive rates.
Our Getting Started bundles provide convenient dose progression, including the Intro Duo (0.25mg and 0.5mg pens) for £169.99 and Progress Duo (0.5mg and 1mg) for £189.99. For patients requiring consistent dosing, our Stay Steady bundles offer two pens of the same strength, such as Consistency 2.4mg (×2) for £419.99. The Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99, ensuring treatment continuity without frequent reordering.
Clinical Evidence: Mounjaro and Wegovy Weight Loss Trial Data
The STEP clinical trial programme provides robust evidence for Wegovy's efficacy in weight management. In the landmark STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 3 demonstrated even greater results of ~16% when combined with intensive behavioural therapy.
Long-term data from STEP 5 showed sustained weight loss of ~15.2% at two years, whilst the recent SELECT trial revealed a 20% reduction in major cardiovascular events. These results reflect controlled clinical trial conditions and individual outcomes may vary. Both Mounjaro and Wegovy clinical trials used different methodologies and patient populations, making direct percentage comparisons inappropriate without clinical context.
How Wegovy and Mounjaro Work: Comparing Mechanisms
Wegovy functions as a GLP-1 receptor agonist, closely mimicking the action of glucagon-like peptide-1, a hormone naturally released in your intestine after eating. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, helping patients feel fuller after consuming smaller portions. The treatment also slows gastric emptying, prolonging the feeling of fullness between meals and potentially reducing food cravings. Mounjaro's dual-action approach targets additional pathways through GIP receptors, which may influence glucose metabolism and fat storage differently. Both treatments require weekly injections and work most effectively when combined with dietary modifications and increased physical activity as part of a comprehensive weight management programme.
Ordering Mounjaro and Wegovy: EverydayMeds Process
Starting your weight loss journey with Mounjaro or Wegovy through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to gather essential medical history and current health information. Our UK-registered prescribers review each application within three working days (express 24-hour service available), ensuring thorough evaluation against MHRA licensing criteria and contraindication screening. Once approved, your prescription-only medicine is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity. Our GPhC-registered pharmacy (#9012878) handles all dispensing with full regulatory compliance and patient safety protocols. Throughout your treatment, our clinical team remains available for ongoing support and prescription renewals as needed.
Storage Requirements: Mounjaro and Wegovy Practical Differences
Storage requirements represent a key practical difference between Mounjaro and Wegovy for UK patients managing their treatment routine. Wegovy FlexTouch pens must be stored in the refrigerator at 2-8°C before first use but offer exceptional travel flexibility, remaining stable at room temperature (below 30°C) for up to six weeks once removed from refrigeration. This storage advantage significantly exceeds Mounjaro's 21-day room temperature limit, making Wegovy more suitable for extended travel or lifestyle flexibility. Both treatments use pre-filled injection pens requiring weekly administration, typically on the same day each week. Dose escalation follows a mandatory schedule starting from the lowest strength, and patients cannot skip escalation steps to minimise side effects and optimise tolerability throughout their weight management journey.
UK Weight Loss Success: Real-World Mounjaro and Wegovy Outcomes
Beyond clinical trial data, UK patients report varying experiences with both Mounjaro and Wegovy, reflecting the individualised nature of weight loss treatment response. Success factors include adherence to prescribed dosing schedules, commitment to dietary modifications, and integration of increased physical activity as recommended by healthcare providers. Some patients respond more favourably to Wegovy's GLP-1-focused mechanism, whilst others may benefit from Mounjaro's dual-action approach, though predicting individual response remains challenging.
NICE guidance (TA875) recommends both treatments within specialist weight management programmes, acknowledging their role in comprehensive obesity treatment. UK prescribers increasingly recognise that optimal outcomes require long-term commitment, as STEP trial extensions demonstrated that patients regained approximately two-thirds of lost weight within one year of stopping treatment. EverydayMeds supports sustained success through ongoing prescriber consultation and treatment continuity planning.
Choosing Between Mounjaro and Wegovy: Expert Guidance
Selecting the most appropriate treatment between Mounjaro and Wegovy requires careful consideration of multiple factors beyond published weight loss percentages. Our experienced UK prescribers evaluate medical history, current medications, lifestyle factors, and individual treatment preferences to guide decision-making. Both treatments are available from EverydayMeds with identical service standards, ensuring patients receive optimal support regardless of their chosen medication. The decision often comes down to practical considerations such as storage requirements, injection frequency tolerance, and previous experience with similar treatments.
Rather than determining which is "better," our clinical approach focuses on which treatment aligns best with each patient's circumstances and weight management goals. Both Mounjaro and Wegovy represent evidence-based options within MHRA-approved indications, and switching between treatments remains possible under prescriber guidance if initial response proves suboptimal. Start your comparison consultation today using discount codes FIRST40 (new customers) or DOSE25 (returning patients) at https://everydaymeds.co.uk/collections/wegovy to access expert guidance on choosing between these leading weight loss treatments.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
